Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Efficacy of zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the efficacy of zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.